Skip to main content
BTAI
NASDAQ Life Sciences

BioXcel Therapeutics 以市价溢价获得 800 万美元注册直接发行

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
8
Price
$1.562
Mkt Cap
$34.151M
52W Low
$1.17
52W High
$8.08
Market data snapshot near publication time

summarizeSummary

BioXcel Therapeutics 宣布向机构投资者进行 4,500,785 股普通股和附带认购权证的 800 万美元注册直接发行。每股 1.739 美元的发行价，加上认购权证，明显高于当前的 1.5616 美元市价，这表明投资者的信心。该融资是在 3 月 5 日宣布的 2 期研究积极的初步结果之后进行的，这可能支持了本次资本筹集的条款。虽然此次发行为公司提供了至关重要的资本，但新股和认购权证的发行将对现有股东产生重大稀释效应，考虑到公司当前的市值。交易者将关注市场对资本注入和稀释效应之间的平衡做出的反应。

在该公告发布时，BTAI的交易价格为$1.56，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3415.1万。 52周交易区间为$1.17至$8.08。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed BTAI - Latest Insights

BTAI
Apr 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
BioXcel Therapeutics Grants Warrants to Lenders, Potentially Diluting Shareholders by Over 5%
Sentiment: Negative
View Wiseek Article
BTAI
Apr 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
DoW-Funded Phase 2a Trial for BioXcel's BXCL501 in Acute Stress Reactions Begins Enrollment
Sentiment: Positive
View Wiseek Article
BTAI
Apr 01, 2026, 6:58 AM EDT
Filing Type: 8-K
Importance Score:
8
FDA Accepts sNDA for At-Home IGALMI® Use, Sets November PDUFA Date
Sentiment: Positive
View Wiseek Article
BTAI
Mar 27, 2026, 5:02 PM EDT
Filing Type: 10-K
Importance Score:
9
BioXcel Therapeutics Discloses Substantial Going Concern Doubt, Reports Increased Losses, and Details Debt Restructuring Amid Clinical Setbacks
Sentiment: Negative
View Wiseek Article
BTAI
Mar 27, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
9
BioXcel Therapeutics Reports Going Concern Doubt, Wider Net Loss, and Decreased IGALMI Revenue
Sentiment: Negative
View Wiseek Article
BTAI
Mar 27, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
BioXcel Therapeutics Beats Q4 Estimates with Narrower Loss, Higher Revenue
Sentiment: Positive
View Wiseek Article
BTAI
Mar 11, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
BioXcel Completes $7.8M Offering, Amends Warrants with Lower Exercise Price and Extended Term
Sentiment: Neutral
View Wiseek Article
BTAI
Mar 11, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
BioXcel Therapeutics Closes $7.8M Registered Direct Offering and Amends Existing Warrants
Sentiment: Neutral
View Wiseek Article
BTAI
Mar 11, 2026, 8:09 AM EDT
Filing Type: 424B5
Importance Score:
8
BioXcel Therapeutics Finalizes $7.3M Registered Direct Offering with Significant Dilution
Sentiment: Neutral
View Wiseek Article
BTAI
Mar 10, 2026, 2:36 PM EDT
Source: GlobeNewswire
Importance Score:
8
BioXcel Therapeutics Secures $8M Registered Direct Offering at Premium to Market Price
Sentiment: Neutral
View Wiseek Article